Bioline Rx Ltd (BLRX) ADR Each Representing 600 Ord Shares UNSPON

Sell:$2.80Buy:$3.00Price increased$0.06 (2.05%)

Prices delayed by at least 15 minutes
Sell:$2.80
Buy:$3.00
Change:Price increased$0.06 (2.05%)
Deal now
Prices delayed by at least 15 minutes
Sell:$2.80
Buy:$3.00
Change:Price increased$0.06 (2.05%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Key people

Aharon Schwartz
Chairman of the Board
Philip Adam Serlin
Chief Executive Officer
Mali Zeevi
Chief Financial Officer
Ella Sorani
Vice President - Development
Abi Vainstein-Haras
Vice President-Clinical & Medical Affairs
Hillit Mannor Shachar
Vice President - Business Development
Michael J. Anghel
Director
Barbara-Jean Bormann
Director
Raphael Hofstein
Director
Sandra Panem
Director
Nurit Benjamini
External Director
Click to see more

Key facts

  • Shares in issue
    2.61bn
  • EPIC
    BLRX
  • ISIN
    US09071M3043
  • Location
    Israel
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $13.51m
  • Employees
    28
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.